|
Sign In to gain access to subscriptions and/or personal tools.
|
Lupus, Vol. 7, No. 9,
622-629 (1998)
DOI: 10.1191/096120398678920758
Outcome criteria for lupus nephritis trials: A critical overview
D T Boumpas
J E Balow
Clinical Investigations Section, Arthritis and Rheumatism Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, and Kidney Disease Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland
Lupus nephritis is an important cause of morbidity and mortality in patients with systemic lupus erythematosus. Traditional outcome criteria such as doubling of serum creatinine, end stage renal disease and death have been used in controlled therapeutic trials, but are limited by their low incidence and the extended period of time required to reach them. More recently, discussions have focused on composite outcome measures, such as remission and relapse, as well as measures of health related quality of life, general lupus activity and cumulative damage indexes. We review the strengths and weaknesses of several outcome criteria, and we propose criteria for both small pilot studies and large definitive trials.
Key Words: hematuria • proteinuria • relapse • remission • serology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
O Traitanon, Y Avihingsanon, V Kittikovit, N Townamchai, T Kanjanabuch, K Praditpornsilpa, J Wongchinasri, K Tungsanga, and S Eiam-Ong
Efficacy of enteric-coated mycophenolate sodium in patients with resistant-type lupus nephritis: a prospective study
Lupus,
August 1, 2008;
17(8):
744 - 751.
[Abstract]
[PDF]
|
|
|
|
|
|
|
Y. E. Chen, S. M. Korbet, R. S. Katz, M. M. Schwartz, E. J. Lewis, and for the Collaborative Study Group
Value of a Complete or Partial Remission in Severe Lupus Nephritis
Clin. J. Am. Soc. Nephrol.,
January 1, 2008;
3(1):
46 - 53.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Ranchin and S. Fargue
Review: New treatment strategies for proliferative lupus nephritis: keep children in mind!
Lupus,
August 1, 2007;
16(8):
684 - 691.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. P. Dhar and R. J. Sokol
Lupus and Pregnancy: Complex Yet Manageable
Clin. Med. Res.,
December 1, 2006;
4(4):
310 - 321.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C E. Barber, L Geldenhuys, and J G Hanly
Sustained remission of lupus nephritis
Lupus,
February 1, 2006;
15(2):
94 - 101.
[Abstract]
[PDF]
|
|
|
|
|
|
|
N. C. T. Kong
Pregnancy of a lupus patient--a challenge to the nephrologist
Nephrol. Dial. Transplant.,
February 1, 2006;
21(2):
268 - 272.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R C. Ravinal, R S Costa, T M Coimbra, M T Pastorello, E B Coelho, M Dantas, and M A dos Reis
Classes, activity and chronicity indices, and {alpha}-smooth muscle actin expression as prognostic parameters in lupus nephritis outcome
Lupus,
February 1, 2002;
11(2):
82 - 87.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M Mosca, R Neri, S Giannessi, A Pasquariello, R Puccini, W Bencivelli, and S Bombardieri
Therapy with pulse methylprednisolone and short course pulse cyclophosphamide for diffuse proliferative glomerulonephritis
Lupus,
April 1, 2001;
10(4):
253 - 257.
[Abstract]
[PDF]
|
|
|
|
|
|
|
K Takada, G G Illei, and D T Boumpas
Cyclophosphamide for the treatment of systemic lupus erythematosus
Lupus,
March 1, 2001;
10(3):
154 - 161.
[Abstract]
[PDF]
|
|
|
|
|
|
|
C C Mok and R W S Wong
Pregnancy in systemic lupus erythematosus
Postgrad. Med. J.,
March 1, 2001;
77(905):
157 - 165.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
J N Siegel
Development of an FDA guidance document for clinical trials in SLE
Lupus,
October 1, 1999;
8(8):
581 - 585.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M Schneider
Response and remission criteria for clinical trials in lupus-- what can we learn from other diseases?
Lupus,
October 1, 1999;
8(8):
627 - 631.
[PDF]
|
|
|
|
